The complete responses in 2/3 patients are a strong early signal in a notoriously difficult-to-treat cancer. Monitor the conference call at 8:30am ET for additional patient details and timeline for FDA feedback on trial continuation. The stock could see significant upside if the data is viewed as de-risking the platform, but the small sample size (n=3) warrants caution — watch for any adverse safety signals or FDA delays.
Price Chart
Executive Summary
Alpha Tau reported groundbreaking interim data from its REGAIN trial for recurrent glioblastoma, showing complete responses in 2 of the first 3 patients with total disappearance of tumor lesions. The data is early (n=3) but highly promising in a devastating disease with few effective treatments, supporting the company's core strategy and potential FDA advancement.
Key Facts
- First 2 of 3 patients demonstrated complete response (total disappearance of all enhancing tumor lesions) per RANO criteria
- Third patient showed stable disease with 30% decrease in tumor dimension
- No local or distant recurrence in any patient as of May 3, 2026 cutoff
- One grade 3 SAE (seizure with temporary paralysis) observed, which resolved with steroids
- Trial expected to enroll up to 10 US patients with recurrent GBM not amenable to surgical resection
- FDA requested interim safety analysis; company awaiting FDA confirmation to continue enrollment
- Glioblastoma has ~14,000 new US cases/year, median survival ~8 months, 5-year survival <10%
Financial Impact
No financial figures disclosed; potential multi-billion dollar market opportunity if Alpha DaRT gains approval for GBM and other brain cancers
Risk Factors
- Very small sample size (n=3) — early data may not replicate in larger cohort
- FDA may require additional safety data or halt enrollment
- Competing therapies (antiangiogenics, checkpoint inhibitors) could limit market adoption
- Company has limited operating history and needs additional funding for commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291734 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access